Ken Griffin X Biotech Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$4.54 - $9.89 $2,270 - $4,945	-500 Reduced 7.94%	5,800 $29,000
Q1 2024 May 15, 2024	BUY	$4.03 - $8.13 $22,165 - $44,715	5,500 Added 687.5%	6,300 $51,000
Q4 2023 Feb 14, 2024	BUY	$3.56 - $4.65 $2,492 - $3,255	700 Added 700.0%	800 $3,000
Q3 2023 Nov 14, 2023	SELL	$4.02 - $5.81 $7,235 - $10,458	-1,800 Reduced 94.74%	100 $0
Q2 2023 Aug 14, 2023	BUY	$3.06 - $6.38 $5,814 - $12,122	1,900 New	1,900 $11,000
Q4 2022 Feb 14, 2023	BUY	$3.03 - $3.79 $5,757 - $7,201	1,900 New	1,900 $6,000

4.67M

5.8K

4.6K

Ticker XBIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,439,300
Market Cap $219M
Description
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.